Current medical guidelines for treating cardiovascular disease seek to reduce LDL-chol (low-density lipoproteins, commonly called “bad cholesterol”) in the blood stream with the long-term aim of limiting or preventing the continued build-up of cholesterol in the vessel walls.
There is indeed no approved medical treatment that rapidly reduces or directly treats atherosclerotic plaque once it has formed. Consequently, the disease is only treated indirectly by reducing cholesterol levels in the blood. Regression and stabilization of plaques has been the holy grail of cardiovascular research for decades.
Commercially available lipid-lowering drugs include statins, intestinal cholesterol absorption inhibitors, fibrates, and bile acid sequestering resins.
The most effective drugs are statins, but they only reduce cardiac risk by about one third.
The oral dyslipidemia products market is well established. In 2013, sales of LDL-lowering products totaled USD 30 billion.
While various interventional cardiology techniques can target the culprit plaques, they fall short of effectively treating additional vulnerable plaques which drive subsequent cardiovascular events, frequently occurring during the same year with fatal outcomes.
As such, there is strong pharmacoeconomic support for a therapy capable of acutely reducing the risk of cardiovascular events. Treatment with an HDL mimetic represents an entirely new market opportunity and could significantly improve outcomes among these patients.
Worldwide Sales 2013
(1) IMS MIDAS
(2) Niacin,Omega 3 therapies